SAN FRANCISCO and RARITAN, N.J., Feb. 8, 2018 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new findings from the Phase 3 SPARTAN clinical trial that showed treatment with ERLEADA™, an investigational, next-generation1 androgen receptor…